FibroGen (FGEN) AI Stock Analysis

• Market Cap: $30.92M
• Dividend Yield: N/A
• Average Volume (3M): 59.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: -38.60%
• EPS Growth: 95.86%
• Country: US
• Employees: 225
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 1.25
• Shares Outstanding: 4,041,759
• 10 Day Avg. Volume: 58,895
• 30 Day Avg. Volume: 59,226
• PEG Ratio: 0.00
• Price to Book (P/B): -69.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.12
• Enterprise Value/Market Cap: 46.36
• Enterprise Value/Revenue: 5.34
• Enterprise Value/Gross Profit: -105.38
• Enterprise Value/Ebitda: -2.52
• 1Y Price Target: $10.00
• Price Target Upside: 30.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 47 Neutral
• Price Target: $8.00 ▲(4.58%Upside)

FibroGen's overall score is primarily driven by its financial instability, with declining revenues and ongoing losses. While technical analysis provides some positive signals, valuation concerns and revenue declines weigh heavily on its investment appeal. Strategic moves highlighted in the earnings call offer some optimism but are overshadowed by financial difficulties.

Positive Factors

Financial Performance

The strong cash balance permits both flexibility and boosts confidence that FG-3246's clinical endeavors can progress without interruption for the foreseeable future.

Pipeline Development

FibroGen remains focused on advancing FG-3246, with upcoming studies that provide multiple shots on goal.

Strategic Transactions

The sale of FibroGen China to AstraZeneca is considered a strategic transaction, providing FibroGen with additional capital and streamlining its portfolio.

Negative Factors

Financial Obligations

The cost reduction program has been completed.

Regulatory Uncertainty

Management conveyed that interactions with the FDA have progressed in a timely manner with no delays, despite investor uncertainties.

Settlement Costs

Announced a settlement related to roxadustat, which will result in a $1.25 million civil penalty paid to FibroGen.

FibroGen Business Overview & Revenue Model

Company Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

How the Company Makes Money

FibroGen generates revenue through the development and commercialization of pharmaceutical products, particularly those related to its proprietary HIF and anti-fibrotic technologies. The company earns money through collaboration agreements, licensing deals, and the sale of its approved drugs. Significant revenue streams include milestone payments and royalties from partnerships with major pharmaceutical companies such as AstraZeneca and Astellas Pharma, which help in the global commercialization of its anemia drug, Roxadustat. These collaborations not only provide upfront and milestone payments but also a share of future sales, contributing significantly to FibroGen's earnings.

FibroGen Financial Statement Overview

Summary

FibroGen is facing significant financial challenges as evidenced by declining revenues, persistent losses, negative stockholders' equity, and negative cash flow. These indicate operational inefficiencies and financial instability that require urgent attention to restore investor confidence.

Income Statement

FibroGen has experienced declining revenue over the past few years, with a significant drop in 2024 compared to previous years. This decline is coupled with persistent negative EBIT and net income, indicating operational challenges and profitability issues. The company also shows negative EBITDA, reflective of its struggles to manage costs effectively amidst falling revenues.

Balance Sheet

The balance sheet reveals high liabilities relative to assets, resulting in negative stockholders' equity, a concerning sign of financial instability. The absence of debt in 2024 is positive, but previous years show reliance on debt, contributing to financial stress. The negative equity ratio further highlights the precarious financial position, indicating significant leverage and risk.

Cash Flow

Operating cash flow has been consistently negative, pointing to challenges in generating cash from core operations. Although free cash flow improved slightly in 2024, it remains negative, indicating cash burn. The cash flow to net income ratios highlight inefficient cash management and an inability to convert revenue into cash profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-23.54M	29.62M	46.80M	140.73M	235.31M	176.32M
Gross Profit	-13.60M	14.06M	42.84M	120.45M	222.44M	167.45M
EBITDA	-127.66M	-142.43M	-305.20M	-282.82M	-274.80M	-164.28M
Net Income	-10.01M	-47.58M	-284.23M	-295.23M	-291.03M	-189.29M
Balance Sheet
Total Assets	165.21M	214.53M	423.53M	610.09M	773.82M	826.84M
Cash, Cash Equivalents and Short-Term Investments	33.61M	50.48M	235.59M	422.01M	405.19M	686.54M
Total Debt	0.00	73.09M	170.46M	89.89M	99.73M	37.72M
Total Liabilities	340.14M	398.16M	585.73M	611.57M	544.71M	385.39M
Stockholders Equity	-174.93M	-183.63M	-204.17M	-21.45M	209.15M	422.18M
Cash Flow
Free Cash Flow	-76.25M	-138.26M	-317.54M	-184.67M	-112.42M	77.61M
Operating Cash Flow	-75.99M	-138.00M	-315.02M	-145.93M	-82.23M	81.60M
Investing Cash Flow	74.70M	125.99M	153.66M	89.12M	-426.97M	452.49M
Financing Cash Flow	-178.00K	-255.00K	122.75M	46.78M	-563.00K	13.34M

FibroGen Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.65
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FGEN, the sentiment is Neutral. The current price of 7.65 is above the 20-day moving average (MA) of 6.21, above the 50-day MA of 7.03, and below the 200-day MA of 9.31, indicating a neutral trend. The MACD of 0.25 indicates Negative momentum. The RSI at 59.56 is Neutral, neither overbought nor oversold. The STOCH value of 86.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FGEN.

FibroGen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥347.74B	11.06	-2.99%	2.56%	11.77%	-10.16%
LVTX	61 Neutral	$37.35M	―	-73.11%	―	-60.20%	3.85%
RNXT	49 Neutral	$47.54M	―	-136.13%	―	―	61.43%
FGEN	47 Neutral	$30.92M	―	60.38%	―	-38.60%	95.86%
GRCE	46 Neutral	$46.46M	―	-14.91%	―	―	75.74%
INKT	38 Underperform	$80.95M	―	78.50%	―	―	55.52%
OSRH	―	$20.43M	―	-25.40%	―	―	―

FibroGen Corporate Events

FibroGen Amends Financing Agreement with Morgan Stanley

On July 14, 2025, FibroGen amended its financing agreement with Morgan Stanley Tactical Value, reducing the minimum cash balance requirement from $22.5 million to $18.75 million. This adjustment may impact FibroGen’s financial flexibility and operational strategies, potentially influencing its market positioning and stakeholder interests.

The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.

FibroGen Enters New Agreement with HiFiBiO

On June 12, 2025, FibroGen entered into a Termination, Asset Transfer and License Agreement with HiFiBiO Inc., ending their previous Exclusive License and Option Agreement. Under the new agreement, FibroGen has licensed its anti-CCR8 and anti-Gal-9 intellectual property to HiFiBiO, with potential financial benefits from sublicensing and commercialization revenues.

The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.

FibroGen Announces Reverse Stock Split Effective June 16

On June 10, 2025, FibroGen, Inc. announced a 1-for-25 reverse stock split of its common stock, effective June 16, 2025. This move aims to increase the stock’s market price to meet Nasdaq’s listing requirements, reducing the number of outstanding shares significantly. The reverse split was approved by stockholders on June 4, 2025, and will affect all outstanding shares and equity incentive plans. Trading on a split-adjusted basis will begin on June 17, 2025.

The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.

FibroGen Amends Financing Agreement for Flexibility

On June 5, 2025, FibroGen amended its financing agreement with Morgan Stanley Tactical Value, reducing its required minimum cash balance from $27 million to $22.5 million, potentially enhancing its financial flexibility. Additionally, on June 4, 2025, FibroGen appointed Dr. Michael Kauffman to its Board of Directors, bringing his extensive oncology expertise to the company, while Dr. Aoife Brennan resigned from the board, with no disagreements cited.

The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.